Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
CD40, a member of the Tumor Necrosis Factor receptor superfamily, is expressed on many tumor
types, including melanoma, prostate, colon, breast, renal, pancreatic, and nonsmall cell lung
cancers. In preclinical models, activation of CD40 results in increased antigen presentation
and induction of apoptosis. CD40 is also expressed on antigen presenting cells (APCs) (B
cells, dendritic cells, monocytes) and is a key regulator of both cellular and humoral immune
responses. Activation of CD40 by CP-870,893, an agonistic anti-CD40 monoclonal antibody,
enhances host immune responses and abrogates the growth of tumors independently of the
expression of CD40 on tumor cells. Therefore, it is hypothesized that therapeutic
intervention with CP-870,893 may be beneficial to a large number of cancer patients either
through an immunomodulatory effect or through a direct effect on CD40-positive tumor cells.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania